Dr Reddy's completes clinical studies of key biosimilar, step closer to launching in US, Europe
The company will collaborate with partner Fresenius Kabi to commercialise the proposed biosimilar for treating illnesses such as arthritis and non-Hodgkin's lymphoma in the US but plans to take the product directly to EU and other regions